二、监事会会议审议情况 经与会监事审议表决，形成的会议决议如下： 证券代码：688293 证券简称：奥浦迈 公告编号：2025-079 上海奥浦迈生物科技股份有限公司 第二届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第二 届监事会第十二次会议于2025年9月2日通过现场表决与通讯相结合的方式召开。 本次会议通知及相关资料已于2025年8月25日送达全体监事。本次会议由监事会 主席梁欠欠女士召集并主持，会议应出席监事3名，实际出席监事3名，本次会议 的召集、召开方式符合相关法律、行政法规、部门规章、规范性文件和《公司章 程》的规定，会议决议合法有效。 1、审议通过了《关于调整公司发行股份及支付现金购买资产并募集配套资 金具体方案的议案》 未超过本次交易中以发行股份方式购买资产的交易价格的100%，配套募集资金 发行股份数量不超过本次交易前上市公司总股本的30%。 除上述调整的内容外，本次交易方案仍按公司20 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-078 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第二 届董事会第十三次会议于2025年9月2日通过现场表决与通讯相结合的方式召开。 本次会议通知及相关资料已于2025年8月25日送达全体董事。本次会议由董事长 肖志华先生召集并主持，会议应出席董事7名，实际出席董事7名，本次会议的召 集、召开方式符合相关法律、行政法规、部门规章、规范性文件和《公司章程》 的规定，会议决议合法有效。 二、董事会会议审议情况 经与会董事审议表决，形成的会议决议如下： 1、审议通过了《关于调整公司发行股份及支付现金购买资产并募集配套资 金具体方案的议案》 结合实际情况，拟对本次交易方案中的配套募集资金方案进行调整，将配套 募集资金总额调整为36,204.99万元，其中，支付本次交易现金对价及税费调整为 34,726.36万元，支付中介机构费用总额调整为1,478.63万元。配套募集资金总额 未超过本次交易中以发行股份方式购买资产的交易价格的100%，配套募集资金 发行股份数量不超过本次交易前上市公司总股本的30%。 除上述调整的内容外，本次交易方案仍 ...

上海奥浦迈生物科技股份有限公司 二、审议通过了《关于确认公司本次交易方案调整不构成重大调整的议案》 第二届董事会独立董事专门会议第五次会议决议 上海奥浦迈生物科技股份有限公司（以下简称"公司"）第二届董事会独立董事 专门会议第五次会议于 2025 年 9 月 2 日通过现场与通讯相结合的方式召开。本次会 议应到独立董事 3 人，实到独立董事 3 人。本次会议的召集、召开程序符合相关法 律、行政法规、部门规章、规范性文件以及《上海奥浦迈生物科技股份有限公司独 立董事工作制度》的规定。 经与会独立董事审议表决，形成的会议决议如下： 一、审议通过了《关于调整公司发行股份及支付现金购买资产并募集配套资金 具体方案的议案》 议案内容：结合实际情况，拟对本次交易方案中的配套募集资金方案进行调整， 将配套募集资金总额调整为 36,204.99 万元，其中，支付本次交易现金对价及税费调 整为 34,726.36 万元，支付中介机构费用总额调整为 1,478.63 万元。配套募集资金总 额未超过本次交易中以发行股份方式购买资产的交易价格的 100%，配套募集资金发 行股份数量不超过本次交易前上市公司总股本的 30%。 除上述调 ...

Group 1 - The biopharmaceutical sector experienced a decline of 0.64% on September 3, with Sai Sheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] - Notable gainers in the biopharmaceutical sector included Baipu Sais, which rose by 12.10% to a closing price of 65.50, and Yuan Yang Crystal Sea, which increased by 9.14% to 32.95 [1] Group 2 - The net capital outflow from the biopharmaceutical sector was 446 million yuan, while retail investors saw a net inflow of 292 million yuan [3] - The table of individual stock capital flows indicates varying levels of investment activity among different companies within the sector [3]

Core Viewpoint - Aopu Mai has shown a stable financial performance with significant growth in revenue and net profit, while its financing activities indicate a low level of leverage and a high level of short selling activity [1][2][3]. Financial Performance - For the first half of 2025, Aopu Mai achieved operating revenue of 178 million yuan, representing a year-on-year growth of 23.77% [2]. - The net profit attributable to the parent company was 37.55 million yuan, reflecting a year-on-year increase of 55.55% [2]. Shareholder and Market Activity - As of June 30, 2025, the number of Aopu Mai shareholders increased to 3,212, up by 6.11% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 5.76% to 24,100 shares [2]. - Aopu Mai has distributed a total of 147 million yuan in dividends since its A-share listing [3]. Financing and Margin Trading - On September 1, Aopu Mai recorded a financing buy amount of 13.18 million yuan and a financing repayment of 14.20 million yuan, resulting in a net financing buy of -1.02 million yuan [1]. - The total margin trading balance for Aopu Mai was 57.56 million yuan, accounting for 1.38% of its market capitalization, which is below the 20th percentile level over the past year, indicating a low leverage position [1]. - In terms of short selling, Aopu Mai had no shares sold or repaid on September 1, with a short selling balance of 0 shares, which is above the 70th percentile level over the past year, indicating a high level of short selling activity [1]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, ICBC Frontier Medical Stock A held 2.90 million shares, an increase of 1.25 million shares from the previous period [3]. - Other notable institutional shareholders include China Merchants Medical Health Industry Stock and a new entrant, China Europe Medical Health Mixed A, which held 1.48 million shares [3].

Core Viewpoint - On September 2, a total of 6 listed companies had their restricted shares unlocked, with a total market value of approximately 5.525 billion yuan [1] Group 1: Company Specifics - Foton Motor (福田汽车) had 1.429 billion shares unlocked, categorized as newly issued A-shares for original shareholders [1] - Xiamen International Trade (厦门国贸) had 396,100 shares unlocked, classified under equity incentive restricted circulation [1] - Greeenme (格林美) had 8.7545 million shares unlocked, also under equity incentive restricted circulation [1] - Starry Sky (启明星辰) had 988,700 shares unlocked, categorized under equity incentive restricted circulation [1] - New Jufeng (新巨丰) had 17.136 million shares unlocked, classified as pre-issue restricted circulation [1] - Aopumai (奥浦迈) had 36.1394 million shares unlocked, with no specific category mentioned [1]

（文章来源：每日经济新闻） 从解禁市值来看，奥浦迈、太湖远大、新巨丰解禁市值居前，解禁市值分别为19.41亿元、2.46亿元、 1.67亿元。 从解禁股数占总股本比例来看，奥浦迈、太湖远大、新巨丰解禁比例居前，解禁比例分别为31.83%、 17.56%、4.08%。 每经AI快讯，Wind数据显示，周二（9月2日），共有6家公司限售股解禁，合计解禁量为6559.5万股， 按最新收盘价计算，合计解禁市值为25.11亿元。 从解禁量来看，奥浦迈、新巨丰、太湖远大解禁量居前，解禁股数分别为3613.94万股、1713.6万股、 893.71万股。 ...

Core Viewpoint - The legal opinion letter from Fangda Partners addresses the adjustments to the stock incentive plan of Shanghai Aopumai Biotechnology Co., Ltd., including the adjustment of grant prices, the cancellation of unvested shares, and the confirmation of vesting conditions for certain stock grants [1][6][19]. Summary by Sections Legal Framework - The legal opinion is based on various Chinese laws and regulations, including the Company Law, Securities Law, and specific guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange [2][3]. Price Adjustment - The stock grant price for the incentive plan was adjusted from 25.00 CNY per share to 24.14 CNY per share, following the calculation of dividends distributed to shareholders [10][11][19]. Cancellation of Shares - A total of 35,000 shares were confirmed to be canceled due to the departure of two incentive recipients who no longer qualified for the incentive program [12][13][19]. Vesting Conditions - The vesting conditions for the first grant's second vesting period and the reserved grant's first vesting period have been met, confirming a total of 297,800 shares eligible for vesting, with 264,000 shares from the first grant and 33,800 shares from the reserved grant [18][19].

证券代码：688293 证券简称：奥浦迈 公告编号：2025-074 通过了《关于确认作废 <公司 ensp="ensp" 年限制性股票激励计划="年限制性股票激励计划"> 部分已授 予尚未归属 上海奥浦迈生物科技股份有限公司 关于确认作废公司 2023 年限制性股票激励计划部分 已授予尚未归属的限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海奥浦迈生物科技股份有限公司（以下简称"公司"或"奥浦迈"）于 2025 年 9 月 1 日召开第二届董事会第十二次会议、第二届监事会第十一次会议，审议 的限制性股票的议案》，现将相关事项公告如下： 一、本次限制性股票授予已履行的决策程序和信息披露情况 《关于 <公司 ensp="ensp" 年限制性股票激励计划="年限制性股票激励计划" 草案="草案"> 及其摘要的 议案》 《关于 <公> 司 2023 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会 授权董事会办理公司股权激励计划相关事宜的议案》等议案，公司独立董事就本 激励计划相关议案发表了 ...

Core Viewpoint - The company has adjusted the grant price of its 2023 restricted stock incentive plan from 24.56 yuan per share to 24.13968 yuan per share, reflecting a necessary adjustment due to dividend distributions and compliance with relevant regulations [1][9][10]. Group 1: Decision-Making Process - The adjustment of the grant price was approved during the second board meeting and the eleventh supervisory board meeting held on September 1, 2025, following the relevant procedures and disclosures [1][3]. - Independent directors provided their opinions on the incentive plan, confirming that the granting conditions have been met and the qualifications of the incentive objects are valid [6][10]. Group 2: Adjustment Reasons and Results - The adjustment was necessitated by the company's mid-year and annual profit distribution, which required recalibration of the grant price according to the incentive plan's provisions [8][9]. - The new grant price was calculated based on the formula P = P0 - V, where P0 is the previous grant price and V is the dividend per share, resulting in an adjusted price of 24.13968 yuan per share [9]. Group 3: Impact of the Adjustment - The adjustment of the grant price will not materially affect the company's financial status or operational results, nor will it impact the stability of the management team or harm the interests of shareholders [9][10]. - The adjustment complies with the management regulations and the incentive plan, ensuring that the process is legal and does not harm the interests of the company or its shareholders [10][11].